We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity
Read MoreHide Full Article
Key Takeaways
IQV leverages more than 1 billion patient records to power analytics, technology and research services.
IQV is expanding across a $330B market with AI, cloud-based tools and real-world solutions.
IQV reported Q1 2026 revenue growth of 8.4% and adjusted earnings growth of 7.4% YoY.
IQVIA Holdings Inc. (IQV - Free Report) is benefiting from strong demand for its vast data resources, favorable healthcare-specific global IT infrastructure and analytics-driven clinical development offerings. Its robust real-world solution ecosystem, innovations and large addressable market size further support its long-term growth. Its shareholder-friendly policies are an added advantage.
However, low liquidity and pricing pressure dampen profitability, scalability and overall financial performance. The company’s non-dividend plans make the stock less attractive to cash dividend-seeking investors.
How Is IQV Faring?
IQV provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company’s vast collection of healthcare information, which encompasses more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media, provides a significant competitive edge over its competitors. It gathers data from healthcare providers, pharmaceutical companies, pharmacies and third-party suppliers, along with EMR systems, claims data, clinical trials and public records. IQV’s unique ability to standardize, organize and integrate this information through sophisticated analytics and its global technology infrastructure helps it build an extensive client base.
The company has an advanced healthcare-specific global IT infrastructure, analytics-driven clinical development capabilities and a robust real-world solutions ecosystem. IQV possesses a growing set of proprietary clinical and commercial applications, which allow it to expand and retain relationships with healthcare stakeholders. This integrated platform, which combines advanced analytics, artificial intelligence (AI) and cloud computing to support life sciences, enables efficient data management, real-time analytics and scalable solutions, driving innovation and improving patient outcomes globally.
IQV’s addressable market consists of outsourced research and development, real-world evidence and connected health and technology-enabled clinical and commercial operations markets. The company is expanding and penetrating these markets by innovating and improving its offerings using its information, advanced analytics, transformative technology and significant domain expertise, which has a value of more than $330 billion.
IQV has showcased a strong commitment to returning value to its shareholders through its share repurchase programs. In the past year alone, the company repurchased shares worth $1.24 billion. Such moves instill shareholder confidence in its stock and generate growth.
Meanwhile, IQV faces pricing pressure from large pharmaceutical companies. Clients are adopting a more cautious approach to their budgets and are increasingly engaged in difficult price negotiations. As a result, the company faces the challenge of balancing competitive pricing with steady profitability as clients seek more cost-effective solutions without compromising the quality of services.
IQV does not offer dividends, leaving share price appreciation as the sole source of returns for its shareholders. This makes the stock less attractive to investors seeking cash dividend returns.
IQV’s current ratio (a measure of liquidity) at the end of the first quarter of 2026 was 0.75, lower than the industry average of 1.8. A current ratio below 1 often indicates that the company may not be well-positioned to pay off its short-term obligations.
IQV reported impressive first-quarter 2026 results. It earned an adjusted profit of $2.90 per share, which topped the Zacks Consensus Estimate by 2.5% and increased 7.4% from the year-ago quarter’s level. Revenues of $4.15 billion surpassed the consensus estimate by 1.6% and rose 8.4% year over year.
Rollins, Inc. (ROL - Free Report) reported impressive first-quarter 2026 results. ROL’s adjusted earnings of 24 cents per share matched the consensus mark and rose 9.1% from the year-ago quarter. ROL’s total revenues of $906.4 million surpassed the consensus mark by 1.3% and increased 10.2% year over year.
Equifax Inc. (EFX - Free Report) reported better-than-expected first-quarter 2026 results. EFX’s adjusted earnings per share of $1.86 beat the Zacks Consensus Estimate by 10.1% and increased 21.6% from the year-ago quarter. EFX’s revenues of $1.6 billion surpassed the consensus estimate by 2.3% and improved 14.4% year over year.
View the Zacks #1 Rank List
Image: Bigstock
Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity
Key Takeaways
IQVIA Holdings Inc. (IQV - Free Report) is benefiting from strong demand for its vast data resources, favorable healthcare-specific global IT infrastructure and analytics-driven clinical development offerings. Its robust real-world solution ecosystem, innovations and large addressable market size further support its long-term growth. Its shareholder-friendly policies are an added advantage.
However, low liquidity and pricing pressure dampen profitability, scalability and overall financial performance. The company’s non-dividend plans make the stock less attractive to cash dividend-seeking investors.
How Is IQV Faring?
IQV provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company’s vast collection of healthcare information, which encompasses more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media, provides a significant competitive edge over its competitors. It gathers data from healthcare providers, pharmaceutical companies, pharmacies and third-party suppliers, along with EMR systems, claims data, clinical trials and public records. IQV’s unique ability to standardize, organize and integrate this information through sophisticated analytics and its global technology infrastructure helps it build an extensive client base.
IQVIA Holdings Inc. Revenues (TTM)
IQVIA Holdings Inc. revenue-ttm | IQVIA Holdings Inc. Quote
The company has an advanced healthcare-specific global IT infrastructure, analytics-driven clinical development capabilities and a robust real-world solutions ecosystem. IQV possesses a growing set of proprietary clinical and commercial applications, which allow it to expand and retain relationships with healthcare stakeholders. This integrated platform, which combines advanced analytics, artificial intelligence (AI) and cloud computing to support life sciences, enables efficient data management, real-time analytics and scalable solutions, driving innovation and improving patient outcomes globally.
IQV’s addressable market consists of outsourced research and development, real-world evidence and connected health and technology-enabled clinical and commercial operations markets. The company is expanding and penetrating these markets by innovating and improving its offerings using its information, advanced analytics, transformative technology and significant domain expertise, which has a value of more than $330 billion.
IQV has showcased a strong commitment to returning value to its shareholders through its share repurchase programs. In the past year alone, the company repurchased shares worth $1.24 billion. Such moves instill shareholder confidence in its stock and generate growth.
Meanwhile, IQV faces pricing pressure from large pharmaceutical companies. Clients are adopting a more cautious approach to their budgets and are increasingly engaged in difficult price negotiations. As a result, the company faces the challenge of balancing competitive pricing with steady profitability as clients seek more cost-effective solutions without compromising the quality of services.
IQV does not offer dividends, leaving share price appreciation as the sole source of returns for its shareholders. This makes the stock less attractive to investors seeking cash dividend returns.
IQV’s current ratio (a measure of liquidity) at the end of the first quarter of 2026 was 0.75, lower than the industry average of 1.8. A current ratio below 1 often indicates that the company may not be well-positioned to pay off its short-term obligations.
IQV reported impressive first-quarter 2026 results. It earned an adjusted profit of $2.90 per share, which topped the Zacks Consensus Estimate by 2.5% and increased 7.4% from the year-ago quarter’s level. Revenues of $4.15 billion surpassed the consensus estimate by 1.6% and rose 8.4% year over year.
IQVIA Holdings currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Recent Earnings Snapshots
Rollins, Inc. (ROL - Free Report) reported impressive first-quarter 2026 results. ROL’s adjusted earnings of 24 cents per share matched the consensus mark and rose 9.1% from the year-ago quarter. ROL’s total revenues of $906.4 million surpassed the consensus mark by 1.3% and increased 10.2% year over year.
Equifax Inc. (EFX - Free Report) reported better-than-expected first-quarter 2026 results. EFX’s adjusted earnings per share of $1.86 beat the Zacks Consensus Estimate by 10.1% and increased 21.6% from the year-ago quarter. EFX’s revenues of $1.6 billion surpassed the consensus estimate by 2.3% and improved 14.4% year over year.